Abstract
Tardive dyskinesia (TD) is a disabling disorder associated with neuroleptic-treatment. Despite the existence of many different therapeutic strategies, TD is often refractory to any treatment. The atypical neuroleptic Clozapine, associated with a relatively low rate of parkinsonism and TD, may have a particular role in the management of neuroleptic-induced TD. The present study will critically analyze the results of the different studies relating to Clozapine's efficacy in TD and its mechanisms. Focus will be on trials wherein the main indication for clozapine's use was the management of TD. Ten of the fourteen relevant studies evaluated, primarily of open design, demonstrated considerable reduction with Clozapine in TD symptomatology in significant proportion of the patients. The dosage required was high, the treatment period long, and cessation of medication was associated with a significant rebound-effect. Clozapine may be efficient in the management of TD. Placebo-controlled designs, employing different dose regiments are required to further establish the role of Clozapine in this disabling disorder.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
